Breast cancer is one of the most common cancer types diagnosed in the world. G1 therapeutics drug trilaciclib may help beat it.
Thanks to regenerative medicine, the accelerated mutation of blood cancer cells can now be augmented via bone marrow or stem cell transplantation.
In the year 2021, the global bone marrow transplant market is forecasted to go beyond the $13 million mark.
Last year, there was a large increase in the demand for global hematology drugs and diagnostics.
Hemogenyx Pharmaceuticals Ltd. will start trading on the London Stock Exchange under the ticker symbol HEMO on Thursday, October 5, 2017.